conbercept

It is used for the treatment of neovascular age-related macular degeneration (nAMD), choroidal neovascularization secondary to pathologic myopia ({{proper name|pmCNV}}),{{cite journal | vauthors = Zhang Y, Han Q, Ru Y, Bo Q, Wei RH | title = Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application | journal = Drug Design, Development and Therapy | volume = 9 | pages = 3413–21 | date = 2015 | pmid = 26170626 | pmc = 4494177 | doi = 10.2147/DDDT.S87920 | doi-access = free }}{{cite journal | vauthors = Yan M, Huang Z, Lian HY, Song YP, Chen X | title = Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia | journal = Acta Ophthalmologica | volume = 97 | issue = 5 | pages = e813–e814 | date = August 2019 | pmid = 30187680 | doi = 10.1111/aos.13632 | s2cid = 52162973 | doi-access = free }} diabetic macular edema (DME).{{cite journal | vauthors = Sun X, Zhang J, Tian J, Chen S, Zeng F, Yuan G | title = Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis | journal = Journal of Ophthalmology | volume = 2020 | pages = 5809081 | date = 2020 | pmid = 32280526 | pmc = 7125465 | doi = 10.1155/2020/5809081 | doi-access = free }} The medication is given through intravitreal injection (IVT).

Conbercept is contraindicated in patients with known hypersensitivity to the active ingredient, in patients with ocular or periocular infections,{{Cite web|title=EU Clinical Trials Register|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004826-14/BG|website=Clinical Trials Register}} and in patients with active intraocular inflammation.

Common adverse effects of the eye formulation include eye pain, transient intraocular pressure (IOP) increase and conjunctival hemorrhage.{{cite journal | vauthors = Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X | display-authors = 6 | title = Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study | journal = Ophthalmology | volume = 121 | issue = 9 | pages = 1740–7 | date = September 2014 | pmid = 24793528 | doi = 10.1016/j.ophtha.2014.03.026 | collaboration = AURORA Study Group | doi-access = free }}{{cite journal | vauthors = Cui J, Sun D, Lu H, Dai R, Xing L, Dong H, Wang L, Wei D, Jiang B, Jiao Y, Jablonski MM, Charles S, Gu W, Chen H | display-authors = 6 | title = Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study | journal = Eye | volume = 32 | issue = 2 | pages = 391–399 | date = February 2018 | pmid = 28937147 | pmc = 5805597 | doi = 10.1038/eye.2017.187 | s2cid = 44026758 | doi-access = free }} (p. 397, Table 2)

Conbercept is a soluble receptor decoy that binds specifically to VEGF-B, placental growth factor (PlGF), and various isoforms of VEGF-A.{{cite journal | vauthors = Stewart MW | title = Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities | journal = Pharmaceutics | volume = 10 | issue = 1 | pages = 21 | date = January 2018 | pmid = 29382038 | pmc = 5874834 | doi = 10.3390/pharmaceutics10010021 | doi-access = free }} Conbercept has a VEGF-R2 kinase insert domain receptor (KDR) Ig-like region 4 (KDRd4) which improves the three-dimensional structure and efficiency of dimer formation, thereby increasing the binding capacity of conbercept to VEGF.{{cite journal | vauthors = Sacconi R, Giuffrè C, Corbelli E, Borrelli E, Querques G, Bandello F | title = Emerging therapies in the management of macular edema: a review | journal = F1000Research | volume = 8 | pages = 1413 | date = 2019-08-12 | pmid = 31448093 | pmc = 6694451 | doi = 10.12688/f1000research.19198.1 | doi-access = free }}

Conbercept is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to the Fc portion of human IgG1 immunoglobulin.{{cite journal | vauthors = Cui C, Lu H | title = Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis | journal = Clinical Interventions in Aging | volume = 13 | pages = 51–62 | date = 2018 | pmid = 29343949 | pmc = 5747960 | doi = 10.2147/CIA.S151225 | doi-access = free }}

Chengdu Kanghong Pharmaceutical Group, a medical company based in Sichuan, started the development of conbercept in 2005.{{Cite web |date=|title=China Focus: Innovation boosts development of China's private medical companies|url=http://www.xinhuanet.com/english/2018-12/17/c_137680388.htm|url-status=dead|archive-url=https://web.archive.org/web/20181217115857/http://www.xinhuanet.com/english/2018-12/17/c_137680388.htm |archive-date=2018-12-17 |access-date=2021-02-05|website=www.xinhuanet.com}} In 2012, the drug was included on the World Health Organization’s Drug Information 67th List of Recommended International Nonproprietary Names,{{Cite web|date=2012|title=International Nonproprietary Names for Pharmaceutical Substances (INN)|url=https://www.who.int/medicines/publications/druginformation/innlists/RL67.pdf?ua=1|website=World Health Organization}} which was the first Chinese innovator biotech drug to be recognized on the list.{{Cite web|title=China Focus: Innovation boosts development of China's private medical companies|url=http://www.xinhuanet.com/english/2018-12/17/c_137680388.htm|url-status=dead|access-date=2021-02-24|website=www.xinhuanet.com|archive-url=https://web.archive.org/web/20181217115857/http://www.xinhuanet.com/english/2018-12/17/c_137680388.htm |archive-date=2018-12-17 }}

In November 2013, the Chinese Food and Drug Administration approved conbercept for the treatment of AMD.{{Cite web |date=|title=The Phase 3 Clinical Trial of Conbercept for Exudative AMD|url=https://www.retinalphysician.com/issues/2019/april-2019/the-phase-3-clinical-trial-of-conbercept-for-exuda|access-date=2021-02-05|website=Retinal Physician}} By 2014, conbercept was marketed for treatment of wAMD in China.{{cite journal | vauthors = Ferro Desideri L, Traverso CE, Nicolò M | title = An update on conbercept to treat wet age-related macular degeneration | journal = Drugs of Today | volume = 56 | issue = 5 | pages = 311–320 | date = May 2020 | pmid = 32406878 | doi = 10.1358/dot.2020.56.5.3137164 | s2cid = 218632826 | url = https://pubmed.ncbi.nlm.nih.gov/32406878/ }} In 2016, Phase III clinical trials of conbercept were authorized by the U.S. Food and Drug Administration.{{ClinicalTrialsGov|NCT03108352|Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion (BRAVE)}}

In 2017, Kanghong Pharmaceutical Group partnered with Syneos Health to process Phase III clinical trials simultaneously in more than 30 countries around the world with an investment of $228 million.{{Cite web|title=创新赋能 责任担当 康弘药业高成长性再获认可 {{!}} 每经网|url=http://www.nbd.com.cn/articles/2019-11-11/1385153.html|access-date=2021-03-15|website=www.nbd.com.cn}} In 2020, conbercept was approved for use in Mongolia.{{Cite web|title=走进"一带一路"，中国创新药康柏西普在蒙古国获批上市--人民健康网--人民网|url=http://health.people.com.cn/n1/2020/0617/c408566-31749766.html|access-date=2021-03-15|website=health.people.com.cn}}

• Conbercept is the only anti-VEGF drug confirmed by randomized controlled trials (RCT) to sustain visual improvements with 3+Q3M regimens (PHOENIX study){{cite journal | vauthors = Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, Chen X, Shen Y, Huang H, Yu L, Ke Z, Rosenfeld PJ, Kaiser PK, Ying G, Sun X, Xu X | display-authors = 6 | title = Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study | journal = American Journal of Ophthalmology | volume = 197 | pages = 156–167 | date = January 2019 | pmid = 30148987 | doi = 10.1016/j.ajo.2018.08.026 | s2cid = 52100991 }}
• Conbercept significantly improves visual acuity and anatomical outcomes in patient with PCV (AURORA Study).{{cite journal | vauthors = Qu J, Cheng Y, Li X, Yu L, Ke X | title = EFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN POLYPOIDAL CHOROIDAL VASCULOPATHY: Subgroup Analysis of the Aurora Study | journal = Retina | volume = 36 | issue = 5 | pages = 926–37 | date = May 2016 | pmid = 26595362 | doi = 10.1097/IAE.0000000000000875 | s2cid = 23512450 | doi-access = free }}
• Conbercept provides significantly visual acuity improvement in DME patients (SAILING study).{{cite journal | vauthors = Wang H, Guo J, Tao S, Wang X, Liu X, Li T, Wang J, Yang X, Niu T, Liu D | display-authors = 6 | title = One-Year Effectiveness Study of Intravitreously Administered Conbercept^® Monotherapy in Diabetic Macular Degeneration: A Systematic Review and Meta-Analysis | journal = Diabetes Therapy | volume = 11 | issue = 5 | pages = 1103–1117 | date = May 2020 | pmid = 32236812 | pmc = 7192996 | doi = 10.1007/s13300-020-00806-0 }}{{clinicalTrialsGov|NCT02194634|Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)}}

• In 2013, the CFDA approved conbercept for the treatment of neovascular age-related macular degeneration (nAMD){{Cite web|title=The Phase 3 Clinical Trial of Conbercept for Exudative AMD|url=https://www.retinalphysician.com/issues/2019/april-2019/the-phase-3-clinical-trial-of-conbercept-for-exuda|access-date=2021-02-17|website=www.retinalphysician.com}}
• In 2017, the CFDA approved it for the treatment of pathologic myopia associated choroidal neovascularization ({{proper name|pmCNV}}) {{Cite web|title=In-depth company research, Kanghong Pharmaceutical|url=http://pg.jrj.com.cn/acc/Res/CN_RES/STOCK/2019/1/10/2537cbf6-711d-4f38-9cb8-f540df3979c0.pdf}}{{Dead link|date=February 2024 |bot=InternetArchiveBot |fix-attempted=yes }}
• In 2019, the CFDA approved it for the treatment of diabetic macular edema (DME)

• Conbercept has been shown to be a cost-effective wAMD treatment option in China. Compared to two similar anti-VEGF intravitreal drugs, ranibizumab and aflibercept, conbercept has been shown to be the most cost-effective option for treatment of wAMD in China.{{cite journal | vauthors = Chen R, Wu B | title = Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration | journal = Annals of Translational Medicine | volume = 8 | issue = 15 | pages = 939 | date = August 2020 | pmid = 32953739 | pmc = 7475432 | doi = 10.21037/atm-20-1334 | doi-access = free }}
• In 2017, the national basic medical insurance in China began covering conbercept.{{cite journal | vauthors = Gao L, Liu J, Zhang P, Ma J, Wang H | title = Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration | journal = Scientific Reports | volume = 10 | issue = 1 | pages = 8010 | date = May 2020 | pmid = 32409739 | doi = 10.1038/s41598-020-65000-5 | pmc = 7224199 | bibcode = 2020NatSR..10.8010G | doi-access = free }}

{{Reflist}}

• [https://druginfo.nlm.nih.gov/drugportal/name/conbercept Conbercept], Drug Information Portal. U.S. National Library of Medicine.

Category:Ophthalmology drugs

Category:Angiogenesis inhibitors

Category:Engineered proteins